Bristol Myers Squibb Snaps up Mirati and Its KRAS-Targeting Cancer Pipeline

In a move to strengthen its KRAS-targeting oncology portfolio, Bristol Myers Squibb is buying Mirati, the company that developed and launched Krazati (adagrasib), a best-in-class molecule that, when combined with a PD-1 inhibitor, targets non-small cell lung cancers harboring the common mutation.
Source: Drug Industry Daily

Leave a Comment

This site uses Akismet to reduce spam. Learn how your comment data is processed.